Xeris Biopharma Holdings, Inc. revises revenue guidance for the full year 2023. For the year, the company tightening revenue guidance from $155 million - $165 million to $160 million - $165 million, which is at the high end of company's original range.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.315 USD | -5.51% | +20.57% | -1.49% |
May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
May. 30 | Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.49% | 344M | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+18.19% | 246B | |
-2.99% | 213B | |
+11.10% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Full Year 2023